新型肿瘤标志物人附睾蛋白4的临床应用  

The clinical application of the new tumor marker of human epididymis 4

作　　者：王雅菲[1] 王丽娟[2] 托娅[1] 

机构地区：[1]内蒙古医科大学研究生学院,内蒙古呼和浩特010059 [2]内蒙古医科大学附属医院检验科,内蒙古呼和浩特100050

出　　处：《分子诊断与治疗杂志》2016年第5期356-360,共5页Journal of Molecular Diagnostics and Therapy

基　　金：内蒙古自治区自然科学基金(2014MS0854)

摘　　要：人附睾蛋白4(human epididymis 4,HE4)是近年来新发现的肿瘤标志物。卵巢癌风险评估(risk of ovarian malignancy algorithm,ROMA)模型通过计算HE4和CA125的联合指数,对于卵巢癌的诊断有较高参考价值。目前血清HE4水平作为卵巢癌诊断、疗效评估及预后判断的新指标已经逐渐应用于临床。亦有研究显示HE4在肺癌患者血清和恶性胸腔积液患者胸水中呈现较高水平表达,提示其在肺癌诊断、预后评估方面的良好作用。本文就HE4在卵巢癌及肺癌的研究现状作一综述,以系统展示HE4的生物学诊断价值。The human epididymis protein 4（HE4） is a novel tumor marker which was discovered in recent years.Risk of ovarian malignancy algorithm（ROMA） model by calculating the combination index of HE4 and CA125,has a high reference value for the diagnosis of ovarian cancer.At present,serum HE4 level as a new indicator for the diagnosis,therapeutic evaluation,and prognosis of ovarian cancer has been applied to the clinic gradually.The existing research shows serum HE4 of patients with lung cancer and HE4 in pleural effusion of patients with malignant pleural effusion presented higher levels of expression,suggesting a promising potential in the diagnosis and the prognosis evaluation of lung cancer.In this paper,the research status of HE4 in ovarian cancer and lung cancer will be reviewed to show its value in the diagnosis of HE4 systematically.

关 键 词：HE4 卵巢癌 肺癌 恶性胸腔积液 

分 类 号：R737.31[医药卫生—肿瘤] R734.2[医药卫生—临床医学]